These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28745431)

  • 1. Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.
    Nakai T; Imura Y; Tamiya H; Yamada S; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
    Cancer Med; 2017 Sep; 6(9):2121-2130. PubMed ID: 28745431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
    Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
    Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
    Martinez-Cruzado L; Tornin J; Rodriguez A; Santos L; Allonca E; Fernandez-Garcia MT; Astudillo A; Garcia-Pedrero JM; Rodriguez R
    Neoplasia; 2017 Jun; 19(6):460-470. PubMed ID: 28494349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
    Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
    Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
    Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
    Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling.
    Nakai S; Tamiya H; Imura Y; Nakai T; Yasuda N; Wakamatsu T; Tanaka T; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Yoshikawa H; Naka N
    Mol Cancer Ther; 2020 Mar; 19(3):742-754. PubMed ID: 31796507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair.
    Harnicek D; Kampmann E; Lauber K; Hennel R; Cardoso Martins AS; Guo Y; Belka C; Mörtl S; Gallmeier E; Kanaar R; Mansmann U; Hucl T; Lindner LH; Hiddemann W; Issels RD
    Int J Cancer; 2016 Jul; 139(2):467-79. PubMed ID: 26933761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin is a promising antitumour agent for synovial sarcoma.
    Yasui H; Imura Y; Outani H; Hamada K; Nakai T; Yamada S; Takenaka S; Sasagawa S; Araki N; Itoh K; Myoui A; Yoshikawa H; Naka N
    J Chemother; 2016 Oct; 28(5):417-24. PubMed ID: 27077926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells.
    Acikgoz E; Guven U; Duzagac F; Uslu R; Kara M; Soner BC; Oktem G
    PLoS One; 2015; 10(10):e0141090. PubMed ID: 26485709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Clear Cell Sarcoma Case: A Diagnostic and Treatment Challenge, with a Promising Response to Trabectedin.
    Galera M; Álvarez R; Arregui M; Paniagua M; Álvarez A; González Crisostomo RA; Díazgranados A; Gutiérrez N; Calles A; Agra C
    Case Rep Oncol; 2023; 16(1):1542-1550. PubMed ID: 38074516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies.
    Takahashi M; Takahashi S; Araki N; Sugiura H; Ueda T; Yonemoto T; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Shimura M; Kawai A
    Oncologist; 2017 Aug; 22(8):979-988. PubMed ID: 28526720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
    Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
    Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
    Mabuchi S; Hisamatsu T; Kawase C; Hayashi M; Sawada K; Mimura K; Takahashi K; Takahashi T; Kurachi H; Kimura T
    Clin Cancer Res; 2011 Jul; 17(13):4462-73. PubMed ID: 21622721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2010 Feb; 70(3):355-76. PubMed ID: 20166769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.
    Uboldi S; Craparotta I; Colella G; Ronchetti E; Beltrame L; Vicario S; Marchini S; Panini N; Dagrada G; Bozzi F; Pilotti S; Galmarini CM; D'Incalci M; Gatta R
    BMC Cancer; 2017 Feb; 17(1):107. PubMed ID: 28166781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabectedin's contribution to the treatment of sarcomas.
    Blay JY
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
    Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
    Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.